北京大学学报(医学版) ›› 2016, Vol. 48 ›› Issue (5): 806-811. doi: 10.3969/j.issn.1671-167X.2016.05.010

• 论著 • 上一篇    下一篇

T3N0M0期肾细胞癌患者预后相关因素分析:单中心182例患者回顾性研究

彭鼎*,李学松*,张崔建△,杨恺惟,唐琦,张雷,余霄腾,何志嵩,周利群△   

  1. (北京大学第一医院泌尿外科,北京大学泌尿外科研究所,国家泌尿、男性生殖系肿瘤诊治中心,北京100034)
  • 出版日期:2016-10-18 发布日期:2016-10-18
  • 通讯作者: 张崔建,周利群 E-mail:surgeon_zhang@126.com, zhouliqunmail@sina.com

Prognostic factors of patients with T3N0M0 renal cell carcinoma: a single-center retrospective study of 182 patients

PENG Ding*, LI Xue-song*, ZHANG Cui-jian△, YANG Kai-wei, TANG Qi, ZHANG Lei, YU Xiao-teng, HE Zhi-song, ZHOU Li-qun△   

  1. (Department of Urology, Peking University First Hospital; Institute of Urology, Peking University; National Urological Cancer Center; Beijing 100034, China)
  • Online:2016-10-18 Published:2016-10-18
  • Contact: ZHANG Cui-jian,ZHOU Li-qun E-mail:surgeon_zhang@126.com, zhouliqunmail@sina.com

摘要:

目的:研究影响T3N0M0期肾细胞癌患者肿瘤学预后的临床及实验室检查因素。方法:回顾性分析2007年至2012年于北京大学第一医院行手术治疗的T3N0M0肾细胞癌患者的临床资料、实验室检查结果及随访数据。应用Kaplan-Meier法计算生存率,Log-rank方法进行单因素分析,对单因素分析中显著相关的变量采用Cox模型进行多因素生存分析。结果:共182例T3N0M0肾细胞癌患者纳入研究,其中男性患者126例(69.23%),女性患者56例(30.77%)。患者平均年龄为(56.75±12.45)岁,中位随访时间48个月(3~99个月),末次随访时共有50例(27.47%)患者死亡,59例患者(32.42%)复发。患者的5年肿瘤特异性生存率为68.30% (95% CI: 60.16%~75.84%),5年无复发生存率为60.70%(95% CI: 53.16%~68.84%)。多因素分析发现,糖尿病(HR=2.434, 95% CI:1.243~4.769, P=0.010)、术前低白蛋白血症(HR=2.188, 95% CI:1.074~1.074, P=0.031)及贫血(HR=3.320, 95% CI:1.839~5.991, P<0.001)是T3N0M0肾细胞癌患者术后肿瘤特异生存的独立危险因素,更高的Fuhrman分级(HR=2.552, 95% CI:1.433~4.545, P=0.001)、术前贫血(HR=2.535, 95% CI:1.497~4.293, P=0.001)是T3N0M0肾细胞癌患者术后复发的独立危险因素。结论:糖尿病、术前低白蛋白血症、贫血是T3N0M0肾细胞癌患者术后生存的独立危险因素;高Fuhrman分级、贫血是T3N0M0肾细胞癌患者术后复发的独立危险因素。

关键词: 肾肿瘤, 癌, 肾细胞, 治疗结果, 肾切除术

Abstract:

Objective: To evaluate the impacts of clinical, pathological, and laboratory factors on oncological outcomes of patients with T3N0M0 renal cell carcinoma. Methods: The clinical data, laboratory exam results, and follow-up outcomes of 182 patients with T3N0M0 renal cell carcinoma who underwent nephrectomy from 2007 to 2012 in Peking University First Hospital were retrospectively collected. The 5-year cancer-specific survival and 5-year recurrence-free survival of all the patients were calculated using Kaplan-Meier method, and the statistical significance between the survival curves were compared using the Logrank test. Variables with significant differences in the univariate analysis were subjected to the multivariate analysis by Cox regression model. All the comparisons were conducted using two-tailed test and P<0.05 was considered statistically significant. Results: A total of 182 patients were included in this study. Of all the 182 patients, 126 were male (69.23%) and 56 were female (30.77%). The mean age was (56.75±12.45) years. The median follow-up time was 48 months (3-99 months). At the end of the follow-up, 50 patients (27.47%) died due to the disease after a median of 29.74 months and 59 patients (32.42%) had tumor recurrence after a median of 22.12 months. The 5-year cancer-specific survival of all patients was 68.30% (95% CI: 60.16%-75.84%); the 5-year recurrencefree survival was 60.70% (95% CI: 53.16%-68.84%). In the univariate analysis, diabetes mellitus, tumor invasion status, Fuhrman grade, serum album, serum cholestenone, anemia, and neutrophils percentage were associated with the cancer-specific survival and Fuhrman grade, serum album and anemia were associated with the recurrence-free survival. Variables with significant differences on univariate analysis were included in Cox multivariate regression analysis. Multivariate Logistic regression analysis showed that diabetes mellitus (HR=2.434, 95% CI: 1.243-4.769, P=0.010), hypoalbuminemia (HR=2.188, 95% CI: 1.074-1.074, P=0.031), and anemia (HR=3.320, 95% CI: 1.839-5.991, P<0.001) were independent risk factors significantly associated with cancerspecific survival; and higher Fuhrman grade (HR=2.552, 95% CI: 1.433-4.545, P=0.001), anemia (HR=2.535, 95% CI: 1.497-4.293, P=0.001) were independent factors significantly associated with recurrence-free survival. Conclusion: Diabetes mellitus, hypoalbuminemia, and anemia were independent risk factors significantly associated with cancer-specific survival of T3N0M0 renal cell carcinoma patients; higher Fuhrman grade and anemia were independent risk factors significantly associated with tumor recurrence of T3N0M0 renal cell carcinoma patients.

Key words: Kidney neoplasms, Carcinoma, renal cell, Treatment outcome, Nephrectomy

中图分类号: 

  • R737.11
[1] 步召德, 冯梦宇, 季科. 早期胃癌行前哨淋巴结导航手术的实践与思考[J]. 北京大学学报(医学版), 2026, 58(2): 239-243.
[2] 王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报(医学版), 2026, 58(2): 251-256.
[3] 罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报(医学版), 2026, 58(2): 257-265.
[4] 付浩, 申潞艳, 黄冰洋, 马少华. 免疫治疗背景下食管鳞状细胞癌围手术期治疗的临床思考[J]. 北京大学学报(医学版), 2026, 58(2): 266-271.
[5] 李伟浩, 张学民, 李伟, 张韬, 张小明. 胸主动脉腔内修复术左肱动脉穿刺点使用血管缝合器处理的临床效果[J]. 北京大学学报(医学版), 2026, 58(2): 388-392.
[6] 殷昊明, 王子杰, 舒帆, 张展奕, 梁会, 张树栋. 肾透明细胞癌FABP6基因长转录本的表达及意义[J]. 北京大学学报(医学版), 2026, 58(2): 393-398.
[7] 李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报(医学版), 2026, 58(2): 399-404.
[8] 郭芷均, 俎明, 马超, 张贺军, 张静, 丁士刚. 同时性多发早期胃癌漏诊病灶的临床病理特征[J]. 北京大学学报(医学版), 2026, 58(2): 410-415.
[9] 潘子晨, 陈凯, 侯钰坤, 杨博涵, 张继新, 马永蔌, 田孝东, 杨尹默. 胰腺腺鳞癌临床病理特征与分子机制研究进展[J]. 北京大学学报(医学版), 2026, 58(2): 431-435.
[10] FarinEbrahimi, 冯志强, FarazEbrahimi, 韩玮华, 于子杨, 贾宽宽, 安金刚. 上颌药物相关性颌骨坏死的不同分期手术治疗效果[J]. 北京大学学报(医学版), 2026, 58(1): 107-114.
[11] 张铃福, 陈明, 赵小宇, 王港, 崔龙, 凌晓锋, 王立新, 徐智, 郭丽梅, 侯纯升. 原发灶局限于胆囊壁内胆囊癌大体分型及其与预后和癌前病变的相关性[J]. 北京大学学报(医学版), 2026, 58(1): 184-189.
[12] 潘莲菲, 李文静, 王瑞洋, 焦剑, 曹战强, 高丽, 释栋. 口服抗生素辅助牙周机械治疗对重度牙周炎的短期疗效及影响因素[J]. 北京大学学报(医学版), 2026, 58(1): 30-36.
[13] 王晓林, 李璐瑶, 张雯, 王鸿雁. 3例子宫体中肾样腺癌的临床病理学分析[J]. 北京大学学报(医学版), 2025, 57(6): 1208-1212.
[14] 侯卫华, 宋书杰, 石中月, 刘露, 金木兰. 食管胃结合部具有显著空泡状核特征的神经内分泌癌1例[J]. 北京大学学报(医学版), 2025, 57(5): 1005-1009.
[15] 谢尚, 王鹿鸣, 张馨元, 冯秋实, 夏洋洋, 戴姿薇, 单小峰, 蔡志刚. 口腔鳞癌类器官库的构建及应用[J]. 北京大学学报(医学版), 2025, 57(5): 847-851.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!